In this prospective , double-blind , placebo-controlled , phase @ trial , postmenopausal patients with early hormone receptor-positive breast cancer receiving treatment with aromatase inhibitors were randomly assigned in a @:@ ratio to receive either denosumab @ mg or placebo administered subcutaneously every @ months in @ trial centres in Austria and Sweden .